Department of Head and Neck Surgery and Otolaryngology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Eur Arch Otorhinolaryngol. 2011 Apr;268(4):481-7. doi: 10.1007/s00405-010-1407-8. Epub 2010 Nov 25.
The treatment of laryngeal and hypopharyngeal cancer nowadays is not limited by surgical resection. There are many interdisciplinary approaches which we can offer these patients in our clinics. These include radiotherapy, chemotherapy, biologicals and surgery. The combination of radiotherapy, chemotherapy, biologicals and surgery techniques more and more allows us to perform organ and function preservation in a former often mutilating and function destroying treatment. Since the early 1990s, evidence from large randomized trials has shown that organ preservation studies using sequential and concomitant radio-chemotherapy do not compromise survival when compared with surgery followed by radiotherapy. However, using these therapies side effects have to be taken into consideration and not organ preservation but function preservation is the treatment goal. The current most common treatment options are shown here in this review. For future treatment protocols there is an urgent need to refine the definition of a functional organ, to define quality of life endpoints and to refine the recommendations for evaluating treatment response.
目前,喉癌和下咽癌的治疗并不仅限于手术切除。在我们的诊所,有许多跨学科的方法可以提供给这些患者。这些方法包括放疗、化疗、生物制剂和手术。放疗、化疗、生物制剂和手术技术的结合越来越多地使我们能够在以前常常是致残和破坏功能的治疗中保留器官和功能。自 20 世纪 90 年代初以来,来自大型随机试验的证据表明,与手术后放疗相比,使用序贯和同期放化疗进行器官保留研究并不会影响生存。然而,使用这些疗法时必须考虑到副作用,而不是器官保留,而是功能保留是治疗目标。目前最常见的治疗选择在本综述中列出。对于未来的治疗方案,迫切需要细化功能器官的定义,定义生活质量终点,并细化评估治疗反应的建议。